Regulations.gov document
Bioavailability Studies Submitted in NDAs or INDs—General Considerations; Guidance for…
Notice · FDA-2018-D-4367 · posted Apr 15, 2022
Key facts
| Document ID | FDA-2018-D-4367-0015 |
|---|---|
| Title | Bioavailability Studies Submitted in NDAs or INDs—General Considerations; Guidance for Industry; Availability |
| Document type | Notice |
| Subtype | Notice of Availability |
| Agency | FDA |
| Docket | FDA-2018-D-4367 |
| Posted | Apr 15, 2022 |
| Federal Register citation | 87 FR 22537 |
| FR document number | 2022-08114 |
| Comment period opens | Apr 15, 2022 |
| Effective date | Apr 15, 2022 |
At a glance
- 1–9 Pages
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: